Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Eyes New Investigational Drug Label Requirements That Bring International Harmonization

Executive Summary

To help reduce medication errors that can harm patients and compromise research results, FDA – pushed by clinical trial sites – looks to exert more control of the labels of investigational drug products.

You may also be interested in...



Lilly CEO: Realistic Expectations Needed For Current Wave of Alzheimer’s Treatments

Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.

New FDA Fecal Transplant Guidance Should Ease Ferring’s Path To Commercialization

Final guidance excludes stool banks, putting in place more limited enforcement discretion regarding the requirement of an investigational new drug application for use of fecal transplants to treat C. diff infections, likely paving way for shift to any FDA-approved product.

Beyond mRNA: FDA’s Marks Calls For Platform Agnostic Search For Better COVID Vaccines

Marks opines on what sponsors would need to do to bring a ‘better’ vaccine to market in a NEJM interview. Meanwhile, CDC releases real world data on estimated bivalent booster efficacy.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel